$163.20
+2.47%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$163.69
From 52W high−3.21%
Volume297451.00
Market cap$308.22B
P/E (TTM)31.1x
P/S (TTM)5.5x
Div yield1.89%
Key dataNov 4, 2026
Open
$163.69
From 52W high
−3.21%
Volume
297451.00
Market cap
$308.22B
ValuationView details →
P/E (Fwd)
16.7x
EV/EBITDA
16.0x
P/E (TTM)
31.1x
RSI (14)
65.9
MomentumView details →
1D Return
+2.47%
YTD Return
+16.12%
SummaryUpdated Sep 1, 2026
Novartis AG (NYSE:NVS) is a Swiss multinational pharmaceutical corporation founded in 1996 through the merger of Ciba-Geigy and Sandoz. Headquartered in Basel, Switzerland, Novartis has evolved into one of the world's largest pharmaceutical companies, focusing on innovative prescription medicines across multiple therapeutic areas. The company completed a significant strategic transformation in 2023 by spinning off its generics division Sandoz, allowing it to focus entirely on developing and commercializing breakthrough treatments for serious diseases.
Similar companies
Latest newsMore news →
NOVARTIS AG Pharma AG notified BioArctic that it had decided to terminate their agreement to explore a potential treatment combining BioArctic’s BrainTransporter technology with a NOVARTIS AG antibody.2d agoNOVARTIS AG reported third-quarter earnings above estimates, with Kisqali, Kesimpta and Scemblix sales offsetting generic competition, while revenue missed estimates.8d agoNOVARTIS AG reported strong third-quarter income, while Kisqali sales fell short of expectations.8d ago